Adlai Nortye Group Ltd（ANL）股票分析ANLAdlai Nortye Group Ltd

Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment. It operates in the Healthcare sector.

Adlai Nortye Ltd (ANL) is currently not a good buy due to its very low RSI of 28.408, indicating that it is oversold, and a significant 5-day price drop of 29.39%. While it has shown impressive year-to-date growth of 699.28%, the recent sharp decline raises concerns. The main risk is the negative earnings per share forecast, with a projected EPS of -0.54 for Q4 2024, which could impact investor sentiment.